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Historically, the most important adverse risk factors for survival
after BMT for AML are Active disease (ActDis), poor-risk cyto-
genetics, and older age. High serum LDH at the time of diagnosis
is an adverse risk factor for survival for AML in the absence of
BMT, but has not been explored as a risk factor in setting of BMT.
We performed a multivariable analysis of these and other potential
risk factors for overall and progression-free survival. From August
1992 to July 2005, we treated 87 patients with AML, who also had
informative cytogenetic studies from the time of diagnosis, with
high-dose busulfan-containing preparative regimens and an HLA-
matched sibling BMT. The median age was 43 years (range 19 to
62). The median LDH level at the time of BMT was 204 U/L
(range 93-1555 U/L; normal 100-220 U/L). Forty-one patients
were in either ﬁrst (n 30) or second complete remission (n11;
CR). 46 patients were with ActDis were treated. The 87 patients
were then classiﬁed according to the SWOG/ECOG (Blood 96:
4075, 2000), MRC (Blood 92:2322, 1998), and CALGB (Blood
100:4325, 2002) cytogenetic classiﬁcation systems. With a median
follow-up of 56.0 months (range 4.5-107.8 months), the median
progression-free survival is 13.5 months for patients in CR1 and
4.1 months for patients in CR2. The progression-free survival of
patients with ActDis was 5.5 months. A Cox proportional hazards
analysis that included gender, age, LDH, disease status, all three
cytogenetic risk groups, preparative regimen, source of stem cells,
and CMV status was performed for overall and progression-free
survival. Signiﬁcant risk factors for shorter survival in univariate
analysis included male gender, LDH 330 U/L (but not LDH
220 U/L or per 100 U/L increase), and peripheral stem cells as
a source of hematopoietic reconstitution (n  7). Surprisingly, a
male donor to a male recipient was also an adverse risk factor
(p0.001). However, in multivariable analysis, only LDH 330
U/L (p0.002), source of stem cells (p0.019), and male donor to
male recipient (p0.001) remained as signiﬁcant adverse risk fac-
tors. In fact, patients with ActDis and an LDH  330 U/L had
similar survival to patients treated in remission, while patients with
ActDis and LDH  330 U/L had signiﬁcantly worse survival. We
conclude that high LDH (1.5X upper limit of normal) at the time
of BMT is a signiﬁcant adverse risk factor for survival after BMT
for AML.
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NOD2/CARD15 GENE SINGLE NUCLEOTIDE POLYMORPHISMS ARE AS-
SOCIATED WITH SIGNIFICANT INCREASES IN MORTALITY DUE TO
INCREASES IN DISEASE RELAPSE IN RECIPIENTS OF AN UNRELATED
DONOR HAEMATOPOIETIC STEM CELL TRANSPLANT FOR ACUTE LEU-
KAEMIA
Mayor, N.P.1,2, Shaw, B.E.1, Hughes, D.A.2, Maldonado-Torres, H.1,2,
Madrigal, J.A.1,2, Keshav, S.3, Marsh, S.G.E.1,2 1Anthony Nolan Re-
search Institute, London, United Kingdom; 2Department of Haematol-
ogy, Royal Free and Univeristy College London School of Medicine,
London, United Kingdom; 3Department of Medicine, Royal Free and
Univeristy College London School of Medicine, London, United Kingdom.
SNPs of the Nucleotide-binding Oligomerisation Domain 2/
Caspase Recruitment Domain 15 (NOD2/CARD15) gene, are
implicated in inﬂammatory disorders, particularly Crohn’s Dis-
ease, Blau syndrome and in the onset and pathogenicity of malig-
nant diseases. NOD2/CARD15 SNPs have also been implicated
with signiﬁcant increases in Transplant Related Mortality and
clinically signiﬁcant acute Graft versus Host Disease post-Haema-
topoietic Stem Cell Transplant (HSCT).
NOD2/CARD15 genotyping was performed on 196 patients
diagnosed with Acute Leukaemia and their volunteer Unrelated
Donors (UD). Transplants occurred between 1996 and 2003 at 25
UK transplant centres. Diagnoses were Acute Lymphoblastic Leu-
kaemia (98/196, 50%) and Acute Myeloid Leukaemia (98/196,
50%). Recipients and donors were a 10/10 HLA allele match
(HLA-A, -B, -C, -DRB1, and -DQB1) in 64% of pairs. Of these,
16% were a 12/12 HLA allele match (also matched at HLA-
DPB1). Myeloablative conditioning regimens were used in 78% of
cases. T-cell depletion was included in 83% of conditioning pro-
tocols, mostly using in-vivo alemtuzumab. Peripheral blood stem
cells were used as a graft in 19% of transplants, with the remaining
81% using bone marrow. Two forms of post-transplant immuno-
suppression predominated, Cyclosporine A and Methotrexate
(47%) and Cyclosporine A alone (31%).
SNPs of the NOD2/CARD15 gene within an UD-HSCT pair
resulted in a signiﬁcant increase in disease relapse and mortality.
The estimated two-year incidence of disease relapse was 43% in
wild type pairs as compared to 70% in pairs with NOD2/CARD15
SNPs (Log rank, P0.0003). The estimated three-year overall
survival was 22% and 44% for pairs with and without NOD2/
CARD15 polymorphisms respectively (Log rank, P0.0087).
These ﬁndings persisted in multivariate analysis. NOD2/CARD15
genotype was found to be the most signiﬁcant factor for an adverse
outcome other than being transplanted in a disease stage of relapse.
In contrast to previous ﬁndings, the presence of NOD2/
CARD15 SNPs in an Acute Leukaemia UD-HSCT pair results in
a signiﬁcant increase in disease relapse and subsequently a decrease
in mortality. These novel data show an important role for NOD2/
CARD15 genotyping in transplantation and suggest a possible
effect of the NOD2 protein in alloreactivity and tumour surveil-
lance. Genotyping recipients and donors prior to transplant may
allow for prediction of transplant outcome, and thus present crit-
ical information for donor selection.
LYMPHOMA/MULTIPLE MYELOMA
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TWO-YEAR FOLLOW-UP RESULTS AT THE M.D. ANDERSON HOSPITAL
WITH REDUCED-INTENSITY ALLOGENEIC STEM CELL TRANSPLANTA-
TION WITH FLUDARABINE-MELPHALAN AS PREPARATIVE REGIMEN IN
RELAPSED/REFRACTORY HODGKIN’S LYMPHOMA
Anderlini, P.1, Saliba, R.1, Acholonu, S.1, Giralt, S.A.1, Khouri, I.F.1,
Andersson, B.1, De Lima, M.1, Hosing, C.1, Champlin, R.E.1 1M.D.
Anderson Hospital, Houston, TX.
Fifty-eight patients with relapsed or refractory Hodgkin’s lym-
phoma (HL) underwent allogeneic stem cell transplantation (allo-
SCT) following a reduced-intensity conditioning (RIC) regimen
from a matched related donor (MRD; n25) or a matched unre-
lated donor (MUD; n33). The median age was 32 years (range
19-59). Forty-eight (83%) patients had received a prior autologous
(auto) SCT. The median time to progression after auto-SCT was
ﬁve months (1-34). Disease status at SCT was sensitive relapse
(n30) or refractory relapse (n28).The conditioning regimen
employed was ﬂudarabine (125-130 mg/m sq over 4-5 days), mel-
phalan (140 mg/m sq IV over 2 days) (FM) and antithymocyte
globulin (thymoglobulin 6 mg/kg over 3 days) was added for the
most recent fourteen MUD transplants. Chimerism studies indi-
cated 100% donor-derived engraftment in all patients (100%).
Cumulative 100-day and 2-year transplant-related mortality
(TRM) were 7% and 15%, respectively, (100-day TRM MRD vs.
MUD 6% vs. 8%, pns; 2-year MRD vs. MUD 13% vs. 16%,
pns). The cumulative incidence of acute (grade II-IV) GVHD
(ﬁrst 100 days) was 28% (MRD vs. MUD 12% vs. 39%, p0.04).
The cumulative incidence of chronic GVHD at any time was 74%
(MRD vs. MUD 57% vs. 89%, p0.003). Fourteen pts (24%)
received a total of 25 (range 1-5) donor leukocyte infusions (DLIs)
for disease progression/relapse (PD). Five of them (35%) received
chemotherapy as well, and nine (64%) developed acute GVHD
after the DLI. Thirty-six patients (62%) are alive (23 in remission)
with a median follow-up of 24 months (4-78). The f/up is 23
months (4-53) for alive pts always in remission. Twenty-two pa-
tients (38%) expired, and relapse-related mortality was 24%. Pro-
jected 2-year overall (OS) and progression-free (PFS) survival are
64% (49-76) and 32% (20-45), with 2-year projected PD at 55%
(43-70). There was no statistically signiﬁcant difference between
MRD and MUD transplants with regard to OS (p0.1), PFS
(p0.9) and PD (p0.8). There was a trend for the response status
prior to allo-SCT (complete response, complete response unde-
ﬁned vs. all others) to favorably impact PFS (p0.07) and PD
(p0.049), but not OS (p0.4). Partial responders and patients
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with stable/ refractory disease fared similarly with regard to OS
and PFS. Day 100, 2-year TRM and OS/PFS data appear very
encouraging in these very high-risk, extensively pretreated pa-
tients. Response status at transplant seems to affect outcome, and
PD remains a major obstacle.
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VACCINATION WITH DENDRITIC CELL MYELOMA FUSIONS ALONE OR
IN CONJUNCTION WITH STEM CELL TRANSPLANTATION FOR PATIENTS
WITH MULTIPLE MYELOMA
Avigan, D.1, Rosenblatt, J.1, Vasir, B.2, Wu, Z.2, Bisonette, A.2,
Macnamarra, C.1, Uhl, L.1, Lenahan, C.1, Miller, K.1, Joyce, R.1,
Levine, J.1, Proper, J.1, Forino, P.1, Donbagoda, D.1, Munshi, N.2,
Kufe, D.2 1Beth Israel Deaconess Medical Center, Boston, MA; 2Dana
Farber Cancer Institute, Boston, MA.
We have demonstrated that patient derived myeloma cells fused
with autologous dendritic cells (DCs) potently stimulate anti-tu-
mor immunity in vitro. We are conducting phase I clinical trials in
which patients with myeloma undergo serial vaccination with DC/
myeloma fusions alone or in conjunction with stem cell transplan-
tation. To date, 18 patients have been enrolled (11- vaccine alone,
7 vaccine following autologous stem cell transplant). To generate
mature DCs, adherent mononuclear cells were isolated from a
leukapharesis collection and cultured with GM-CSF, IL-4, and
TNF . The mean yield and viability of the DC preparations was
1.5  108 cells and 88%, respectively. Patient derived myeloma
cells were isolated from bone marrow aspirates and were quantiﬁed
by the expression of CD38 and/or CD138. The mean yield and
viability of the myeloma cell collections was 7.3  107 cells and
89%, respectively. Fusion cells were generated by coculture of
DCs with myeloma cells in the presence of 50% polyethylene
glycol. The mean fusion efﬁciency was 40% as determined by the
percentage of cells that co-expressed unique DC and myeloma
antigens. In contrast to myeloma cells, the DC and fusion cell
preparations prominently stimulated allogeneic T cell proliferation
in vitro. To date, 13 patients have completed vaccination at a dose
of 1-5  106 fusion cells. GM-CSF (100 g) was administered
subcutaneously on the day of vaccination and for 3 days thereafter.
Adverse events judged to be potentially vaccine related have in-
cluded vaccine injection site reactions, edema, rash, fever, chills,
fatigue, muscle aches, pruritis, and diarrhea. One patient with a
history of prior deep venous thrombosis (DVT) developed a DVT
and pulmonary embolus of uncertain relation to the vaccine. To
date, a majority of evaluable patients demonstrated evidence of
vaccine induced anti-myeloma immunity as demonstrated by at
least 2 fold increase in IFN expression by CD4 and/or CD8 T
cells in response to ex vivo exposure to autologous tumor lysate. Of
patients undergoing vaccine therapy alone, 5 patients demon-
strated stabilization of the myeloma paraprotein for 2-6 months
following initiation of vaccination. Of 3 patients completing post-
transplant vaccination, 2 patients demonstrated resolution of the
persisting myeloma protein post-transplant and 1 patient demon-
strated a transient increase followed by a decline in paraprotein
levels post-transplant.
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INTERLEUKIN-6 AND HEMATOPOIETIC SOLUBLE FACTORS CONFERS
RESISTANCE TO TRAIL MEDIATED APOPTOSIS
Perez, L.E.1, Parquet, N.1, Shain, K.2, Molisano, M.1,
Nimmanapalli, R.2, Alsina, M.1, Anasetti, C.1, Dalton, W.2 1BMT
Division, H. Lee Mofﬁtt Cancer Center, Tampa, FL; 2Hematology
Division, H. Lee Mofﬁt Cancer Center, Tampa, FL.
The bone marrow microenvironment provides tumor protection
from chemotherapy and Fas-death receptor mediated apoptosis
through a process known as environmental mediated death resis-
tance (EM-DR). TRAIL, a member of the TNF superfamily, has
anti-tumor activity sparing normal cells and mediates allogeneic
graft-versus-tumor responses. We hypothesized that the tumor
microenvironment inﬂuences TRAIL mediated killing conferring
an immune resistance mechanism contributing to cancer progres-
sion in allogeneic transplantation. Experiments in a transwell
(TW) assay with RPMI-8226-Myeloma cells in the upper well and
HS5- hematopoietic stromal cells in the bottom well (TWHS5)
revealed that HS5 cells blocked recombinant human(rh-) TRAIL-
induced apoptosis through soluble factors in a dose and time-
dependent manner. RPMI-8226 treated in TWHS5 exhibited
attenuated pro-caspase-8, pro-caspase-3, PARP, and BID cleavage,
with diminished mitochondrial membrane potential changes, with-
out alterations on TRAIL receptors. Western blotting of RPMI-
8226 cells showed that Fas-associated death domain like IL-1
converting enzyme-like inhibitory protein (FLIP), a regulatory
factor that competes with caspase-8 inhibiting apoptosis, is in-
creased in TWHS5 treated cells. Subcellular fractionation of
RPMI-8226 cells showed that FLIP is maintained in or associated
with organelle membranes and is released to the cytosol when
exposed to soluble factor (TWHS5) suggesting that that soluble
factor signaling may inﬂuence FLIP localization and availability.
FLIP reduction by FLIP-RNA interference or with Bortezomib,
NF-KB inhibitor that reduces FLIP levels, increases TRAIL apo-
ptosis sensitivity of RPMI-8226 cells treated in TWHS5. To
explore whether IL-6, important myeloma survival factor, is in-
volved in TRAIL-EMDR, RPMI-8226 treated with HS27a stroma
that lack IL-6 secretion elicit a diminished apoptosis resistance
compared to HS-5. In addition, RPMI-8226 treated in TWHS5
with an anti-human IL-6 neutralizing antibody partially overcome
the TRAIL apoptosis resistance. Furthermore, rh-IL-6 confers
resistance to TRAIL mediated apoptosis in a dose-dependent man-
ner associated with FLIP increase. Our results suggest that IL-6
and other soluble factors produced by marrow stromal cells pro-
mote myeloma cell survival by upregulating FLIP, thereby miti-
gating the inﬂuence of the microenvironment on TRAIL-induced
apoptosis. The immune cytotoxic effect of TRAIL may be en-
hanced by FLIP inhibitors.
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THE USE OF CYCLOPHOSPHAMIDE (CY), FLUDARABINE AND ATG AS A
PREPARATIVE REGIMEN FOR UNRELATED CORD BLOOD TRANSPLAN-
TATION (UCBT) IN FANCONI ANEMIA: A SINGLE CENTER EXPERIENCE
IN 27 PATIENTS
Bonﬁm, C.1, Bitencourt, M.1, Setubal, D.1, Funke, V.1, Ruiz, J.1,
Oliveira, M.1, Coutinho, E.1, deMedeiros, C.1, Zanis-Neto, J.1,
Pasquini, R.1 1Stem Cell Transplantation Unit UFPR, Curitiba,
Parana, Brazil.
Stem cell transplantation from HLA identical siblings can cure
over 80% of FA pts when they develop bone marrow failure
syndromes. Unrelated CB is a good option for pts lacking a
matched bone marrow unrelated donor, but the transplant pro-
cedure is complicated by a high incidence of graft failure and
delayed immune recovery. From 01/03 to 05/06 we transplanted
27pts with FA in aplastic phase. Gender: 8M/19F. Age:4-
19years (M:8y). Disease duration: 19-78months (M:36m). Pre-
vious transfusions : 1-85UI (M:12) .HLA Compatibility: 6/6:
3pts ; 5/6:9pts and 4/6:15pts. Preparatory regimen: CY60mg/
kg Fludarabine125mg/m2  Rabbit ATG 4mg/kg. GVHD
Prophylaxis: Cyclosporine (Csa)  steroids:22pts or Csa 
MTX: 5pts.TNC infused before thawing: 2,3 – 19,2 10^7/kg
(M: 5,4). One pt received a double UCBT with a TNC of 5,2
10^7. Results: 11pts are alive between 135-1301 days after
UCBT(M: 806d). 21pts survived  28 d and were evaluable for
engraftment. 13pts (48%) had a complete hematological recov-
ery and the median time to reach ANC500/ul was 23 d(12-
35d) and platelets  20.000/ul was 27 d(15-50d). Primary graft
failure occurred in 6pts and 2pts had only a neutrophil engraft-
ment. Most pts (6/8pts) without hematological recovery re-
ceived a 4/6 CB. No pt survived a 2nd or 3rd UCBT. Post-
transplant complications: Mucositis grade III-IV: 10pts (grade
IV: 1pt). Hemorrhagic cystitis: 5pts.Hemolytic uremic syn-
drome:1pt. Moderate/severe hypertension: 70% of pts. Neuro-
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